Paper33388161
Programmed death ligand-1 (PD-L1) as a predictive marker for immunotherapy in solid tumours: a guide to immunohistochemistry implementation and interpretation.
Paver EC and 10 others. Pathology, 2021. Cited by 211 papers, by iCite.
Cite this record
ConductScience Library. Programmed death ligand-1 (PD-L1) as a predictive marker for immunotherapy in solid tumours: a guide to immunohistochemistry implementation and interpretation. Papers, record 33388161. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/33388161
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- Programmed death ligand-1 (PD-L1) as a predictive marker for immunotherapy in solid tumours: a guide to immunohistochemistry implementation and interpretation.
- PubMed
Topics24
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| B7-H1 Antigen | Major topic |
| Biomarkers, Tumor | Major topic |
| Neoplasms | Major topic |
| Carcinoma, Hepatocellular | |
| Carcinoma, Non-Small-Cell Lung | |
| Carcinoma, Renal Cell | |
| Carcinoma, Transitional Cell | |
| Colorectal Neoplasms | |
| Diagnostic Tests, Routine | |
| Endometrial Neoplasms | |
| Female | |
| Head and Neck Neoplasms | |
| Humans | |
| Immune Checkpoint Inhibitors | |
| Immunohistochemistry | |
| Immunotherapy | |
| Kidney Neoplasms | |
| Liver Neoplasms | |
| Male | |
| Melanoma | |
| Neoplasm Grading | |
| Prognosis | |
| Programmed Cell Death 1 Receptor | |
| Triple Negative Breast Neoplasms |
Source PubMed
Cited by146
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 211 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 42972057 | The genomic and epigenomic evolution of colorectal cancer. | Nat Rev Gastroenterol Hepatol | 2026 | https://conductscience.org/library/papers/42972057 | PubMed |
| 42949705 | Label-free Raman spectroscopy for cancer therapy response: from methodological framework to clinical translation. | Chem Soc Rev | 2026 | https://conductscience.org/library/papers/42949705 | PubMed |
| 42882767 | Next-Generation Immunohistochemical and RNA in Situ Hybridization Assays for Renal Neoplasia: Which Biomarkers Are Ready for Prime Time? | Cancers (Basel) | 2026 | https://conductscience.org/library/papers/42882767 | PubMed |
| 42816549 | Development of functional spatial mapping of the tumour immune microenvironment (FuncO:TiME) in advanced melanomas. | BJC Rep | 2026 | https://conductscience.org/library/papers/42816549 | PubMed |
| 42684559 | Cytokines and chemokines in plasma as markers reflecting immunophenotype of head and neck squamous cell carcinoma. | Hum Cell | 2026 | https://conductscience.org/library/papers/42684559 | PubMed |
| 42614979 | Prognostic Factors Analysis in Patients with Hepatocellular Carcinoma Receiving PD-1/PD-L1 Inhibitors. | J Hepatocell Carcinoma | 2026 | https://conductscience.org/library/papers/42614979 | PubMed |
| 42570161 | Deciphering the immune landscape of parathyroid carcinoma: implications for immunotherapeutic responsiveness. | Endocrine | 2026 | https://conductscience.org/library/papers/42570161 | PubMed |
| 42397400 | Multidimensional analysis of tumour immune microenvironment in HCC: prognostic significance and implications for immunotherapy. | Cancer Immunol Immunother | 2026 | https://conductscience.org/library/papers/42397400 | PubMed |
| 42218596 | From Tumour to Bloodstream: Advancing PD-L1 Testing With Liquid Biopsies in Non-Small Cell Lung Cancer. | Cytopathology | 2026 | https://conductscience.org/library/papers/42218596 | PubMed |
| 42169955 | PD-1/PD-L1 expression and predictive value of efficacy in hepatocellular carcinoma patients with anti-PD-1 therapy: a real-world study. | J Gastrointest Oncol | 2026 | https://conductscience.org/library/papers/42169955 | PubMed |
| 42122148 | PD-L1-Guided Chemo-Immunotherapy in Advanced Triple-Negative Breast Cancer: A Meta-Analysis of Survival Benefits and Toxicity Profiles. | Cancers (Basel) | 2026 | https://conductscience.org/library/papers/42122148 | PubMed |
| 42075598 | The Correlation Between PD-L1 Expression in Metaplastic Breast Cancer and Clinical-Pathological Features and Prognosis. | Medicina (Kaunas) | 2026 | https://conductscience.org/library/papers/42075598 | PubMed |
| 42003937 | Comprehensive treatment for intracranial invasive sinonasal intestinal-type adenocarcinoma with a focus on radiotherapy dosage and immunological combination therapy: A case report. | Oncol Lett | 2026 | https://conductscience.org/library/papers/42003937 | PubMed |
| 41836111 | The Age of Molecular Biomarkers: Cancer in the Era of Personalized Medicine. What Do Pathologists in Developing Countries Need to Know and Understand? | Int J Gen Med | 2026 | https://conductscience.org/library/papers/41836111 | PubMed |
| 41798957 | Neoadjuvant chemotherapy-induced immune remodeling in ovarian cancer: implications for TIL dynamics and combination immunotherapy. | Front Immunol | 2026 | https://conductscience.org/library/papers/41798957 | PubMed |
| 41766893 | A composite biomarker based on early dynamic changes in lactate dehydrogenase and PD-L1 expression enhances outcome prediction for immunochemotherapy in HER2-negative advanced gastric cancer. | Front Immunol | 2026 | https://conductscience.org/library/papers/41766893 | PubMed |
| 41677996 | The progress of biomarkers detection to lung cancer. | Discov Oncol | 2026 | https://conductscience.org/library/papers/41677996 | PubMed |
| 41626182 | Research progress on the impact and mechanisms of helicobacter pylori infection on the efficacy of immunotherapy for gastric cancer. | Front Oncol | 2025 | https://conductscience.org/library/papers/41626182 | PubMed |
| 41578901 | Immunoexpression of programmed death receptor 1 and its ligands in oral cavity squamous cell carcinoma. | Med Oral Patol Oral Cir Bucal | 2026 | https://conductscience.org/library/papers/41578901 | PubMed |
| 41533174 | Ultrasensitive biosensor based on AgNPs-functionalized perylene derivative nanosheets with enhanced electrochemiluminescence at narrow potential sweep range. | Mikrochim Acta | 2026 | https://conductscience.org/library/papers/41533174 | PubMed |
Genes2
The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.
| Gene | NCBI Gene ID | Linked by | In Genes | Source |
|---|---|---|---|---|
| CD274 | 29126 | PubTator's text mining | https://conductscience.org/library/genes/29126 | NCBI Gene |
| PDCD1 | 5133 | PubTator's text mining | https://conductscience.org/library/genes/5133 | NCBI Gene |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- Comments and corrections
- References
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/33388161
GET https://conductscience.org/api/papers/v1/33388161/cited_by?page=2